Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Verrica Pharmaceuticals (VRCA)
NASDAQ:VRCA
RESEARCH TOOLSreports
Verrica Pharmaceuticals (VRCA) Stock Price & Analysis
298 Followers
VRCA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.86 - $7.76
Previous Close$5.65
Volume92.02K
Average Volume (3M)157.83K
Market Cap
$239.66M
Enterprise Value$199.18M
Total Cash (Recent Filing)$84.30M
Total Debt (Recent Filing)$43.82M
Price to Earnings (P/E)-3.9
Beta0.61
Next Earnings
May 07, 2024EPS Estimate
-$0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.46
Shares Outstanding42,418,553
10 Day Avg. Volume144,064
30 Day Avg. Volume157,828
Standard Deviation0.28
R-Squared0.12
Alpha0.00259
Financial Highlights & Ratios
Price to Book (P/B)11.42
Price to Sales (P/S)3524.48
Price to Cash Flow (P/CF)-3.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue62.17
Enterprise Value/Gross Profit22.05
Enterprise Value/Ebitda-8.49
Forecast
1Y Price Target
$12.50Price Target Upside111.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Verrica Pharmaceuticals News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
VRCA FAQ
What was Verrica Pharmaceuticals’s price range in the past 12 months?
Verrica Pharmaceuticals lowest stock price was $2.86 and its highest was $7.75 in the past 12 months.
What is Verrica Pharmaceuticals’s market cap?
Currently, no data Available
When is Verrica Pharmaceuticals’s upcoming earnings report date?
Verrica Pharmaceuticals’s upcoming earnings report date is May 07, 2024 which is in 18 days.
How were Verrica Pharmaceuticals’s earnings last quarter?
Verrica Pharmaceuticals released its earnings results on Feb 29, 2024. The company reported -$0.53 earnings per share for the quarter, beating the consensus estimate of -$0.562 by $0.032.
Is Verrica Pharmaceuticals overvalued?
According to Wall Street analysts Verrica Pharmaceuticals’s price is currently Undervalued.
Does Verrica Pharmaceuticals pay dividends?
Verrica Pharmaceuticals does not currently pay dividends.
What is Verrica Pharmaceuticals’s EPS estimate?
Verrica Pharmaceuticals’s EPS estimate is -$0.45.
How many shares outstanding does Verrica Pharmaceuticals have?
Verrica Pharmaceuticals has 42,418,552 shares outstanding.
What happened to Verrica Pharmaceuticals’s price movement after its last earnings report?
Verrica Pharmaceuticals reported an EPS of -$0.53 in its last earnings report, beating expectations of -$0.562. Following the earnings report the stock price went down -7.867%.
Which hedge fund is a major shareholder of Verrica Pharmaceuticals?
Among the largest hedge funds holding Verrica Pharmaceuticals’s share is Perceptive Advisors LLC. It holds Verrica Pharmaceuticals’s shares valued at 52M.
---
Verrica Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.50 (111.15% Upside)
$12.50 (111.15% Upside)
Blogger Sentiment
Bullish
VRCA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 2.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 6.9%
Last 30 Days ▼ 6.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-8.50%
12-Months-Change
Fundamentals
Return on Equity
-224.08%
Trailing 12-Months
Asset Growth
82.46%
Trailing 12-Months
Company Description
Verrica Pharmaceuticals
Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product VP-102, is a proprietary topical therapy used in common skin indications including Molluscum contagiosum and Verruca Vulgaris. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.
---
VRCA Earnings Call
Q4 2024
0:00 / 0:00
---
VRCA Stock 12 Months Forecast
Average Price Target
$12.50
▲(111.15% Upside)
Technical Analysis
Best Analysts Covering VRCA
1 Year
1 Year Success Rate
16/30 ratings generated profit
1 Year Average Return
+6.72%
reiterated a buy rating 2 months ago
Copying Oren Livnat's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +6.72% per trade.
---